YU68299A - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions

Info

Publication number
YU68299A
YU68299A YU68299A YU68299A YU68299A YU 68299 A YU68299 A YU 68299A YU 68299 A YU68299 A YU 68299A YU 68299 A YU68299 A YU 68299A YU 68299 A YU68299 A YU 68299A
Authority
YU
Yugoslavia
Prior art keywords
compositions
solubilized
solubilized sertraline
sertraline compositions
sertraline
Prior art date
Application number
YU68299A
Other languages
Serbo-Croatian (sh)
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU68299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU68299A publication Critical patent/YU68299A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Abstract

Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
YU68299A 1997-07-01 1998-06-15 Solubilized sertraline compositions YU68299A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
YU68299A true YU68299A (en) 2002-06-19

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
YU68299A YU68299A (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (en)
JP (1) JP2000514100A (en)
KR (1) KR100366373B1 (en)
CN (1) CN1261794A (en)
AP (1) AP1192A (en)
AR (3) AR015917A1 (en)
AU (1) AU742535B2 (en)
BG (1) BG103918A (en)
BR (1) BR9810739A (en)
CA (1) CA2290974C (en)
CO (1) CO4940495A1 (en)
DZ (1) DZ2548A1 (en)
EA (1) EA002481B1 (en)
HN (1) HN1998000102A (en)
HR (1) HRP980377A2 (en)
HU (1) HUP0002236A3 (en)
ID (1) ID23429A (en)
IL (1) IL133076A (en)
IS (1) IS5260A (en)
MA (1) MA24587A1 (en)
NO (1) NO996520L (en)
OA (1) OA11243A (en)
PA (1) PA8454301A1 (en)
PE (1) PE97199A1 (en)
PL (1) PL337804A1 (en)
SK (1) SK181099A3 (en)
TN (1) TNSN98124A1 (en)
TR (1) TR199903297T2 (en)
TW (1) TW550087B (en)
UA (1) UA67741C2 (en)
UY (1) UY25071A1 (en)
WO (1) WO1999001120A1 (en)
YU (1) YU68299A (en)
ZA (1) ZA985708B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200357A (en) 1999-12-23 2003-10-15 Pfizer Products Inc. Pharmaceutical compositions providing increased concentrations of the drug substance
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP2004507502A (en) 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク Sustained release formulation for growth hormone secretagogue
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
EP2520300A4 (en) * 2009-12-29 2013-05-08 Kowa Co Pharmaceutical composition for oral administration
WO2011081117A1 (en) * 2009-12-29 2011-07-07 興和株式会社 Solid pharmaceutical composition for oral administration
CN109908354A (en) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 Sertraline hydrochloride takes orally concentrate and its preparation process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (en) * 1989-08-30 1993-11-15 Pfizer USE OF SERTRALINE TO TREAT CHEMICAL ADDICTION.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
BG103918A (en) 2000-07-31
SK181099A3 (en) 2000-07-11
KR20010013365A (en) 2001-02-26
AP1192A (en) 2003-07-23
PL337804A1 (en) 2000-09-11
UA67741C2 (en) 2004-07-15
AR015917A1 (en) 2001-05-30
HUP0002236A2 (en) 2003-08-28
CA2290974C (en) 2004-04-27
IL133076A (en) 2003-12-10
ZA985708B (en) 2000-01-10
NO996520L (en) 2000-02-29
EA199900962A1 (en) 2000-08-28
KR100366373B1 (en) 2003-01-14
PE97199A1 (en) 1999-10-05
IL133076A0 (en) 2001-03-19
CA2290974A1 (en) 1999-01-14
UY25071A1 (en) 2000-12-29
AR040279A2 (en) 2005-03-23
AR040280A2 (en) 2005-03-23
DZ2548A1 (en) 2003-02-08
IS5260A (en) 1999-11-19
WO1999001120A1 (en) 1999-01-14
EP0999829A1 (en) 2000-05-17
NO996520D0 (en) 1999-12-28
BR9810739A (en) 2000-09-12
HN1998000102A (en) 1999-01-08
TR199903297T2 (en) 2000-07-21
TNSN98124A1 (en) 2005-03-15
EA002481B1 (en) 2002-06-27
CN1261794A (en) 2000-08-02
PA8454301A1 (en) 2000-09-29
TW550087B (en) 2003-09-01
JP2000514100A (en) 2000-10-24
AU7544898A (en) 1999-01-25
AP9801280A0 (en) 1998-06-30
MA24587A1 (en) 1998-12-31
ID23429A (en) 2000-04-20
CO4940495A1 (en) 2000-07-24
HUP0002236A3 (en) 2003-12-29
HRP980377A2 (en) 1999-04-30
AU742535B2 (en) 2002-01-03
OA11243A (en) 2003-07-24

Similar Documents

Publication Publication Date Title
GB9717905D0 (en) Lipid-containing compositions and uses thereof
ZA995601B (en) Water-soluble pharmaceutical composition in an ionic complex and the use thereof.
EP1017427A4 (en) Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion
HUP0103267A3 (en) High-strength aqueous glyphosate concentrate and use thereof
EP0680694A3 (en) Compositions of fluorescent biocides for use in aqueous systems.
AU3117397A (en) Fire-fighting agents containing polysaccharides and fluorochemical oligomeric surfactants
NZ239879A (en) Cleansing composition comprising two amphoteric surfactants-one being an imidazolinium derivative, the other an aminoalkanoate or iminodialkanoate, and an insoluble conditioning agent
AU7597898A (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
YU68299A (en) Solubilized sertraline compositions
HUP0103636A3 (en) 2-methyl-thieno-benzodiazepine formulation and its use
ZA200102956B (en) Use of ophthalmic composition comprising vitamin A and Vitamin E.
ZA949151B (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents.
AU1887399A (en) Aqueous compositions comprising complexing agents and uses therof
EP0610010A3 (en) Liquid compositions comprising bleaching and/or hygiene agents of low aqueous solubility.
AU2600499A (en) Methods and compositions comprising the use of blocked b-amyloid peptide
AU6519198A (en) Melaninization inhibitor, skin-care preparation, and bath agent
BG104825A (en) Ophthalmic solution comprising glycogen
BG104914A (en) Paroxetine maleate
MY119728A (en) Encapsulated solution dosage forms of sertraline
EP0657522A3 (en) Salt compositions and functional fluids using same.
GB9802542D0 (en) New use
MD980129A (en) Antiherpetic remedy
PL347545A1 (en) Case-safe system
HU0103040D0 (en) High - level source and it's application
ECSP982572A (en) SOLTRILIZED COMPOSITIONS OF SERTRALINA